Japan's Shionogi Sues Sawai, Claiming Patent Violation For Antibiotic
This article was originally published in PharmAsia News
Two Japanese pharmaceutical companies are headed for court over a generic version of a branded biotic drug. Shionogi has sued Sawai Pharmaceutical, saying it violated the plaintiff's patent for the crystallization technique used in making Flomox (cefcapene). Shionogi's cefcapene patent expired last October and Sawai began marketing a generic of it in May. Shionogi said its crystallization patent, however, remains effective through March 2011, and that Sawai's generic violates it. (Click here for more - a subscription may be required
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.